Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$2.78 USD
-0.13 (-4.47%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $2.79 +0.01 (0.36%) 5:46 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Compass Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CMPX 2.78 -0.13(-4.47%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Other News for CMPX
Compass Therapeutics (CMPX) Receives Outperform Rating from Raymond James | CMPX Stock News
Compass Therapeutics resumed with an Outperform at Raymond James
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler
Compass Therapeutics management to meet virtually with Piper Sandler